User login
Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2
*Click on the links to the left for PDFs of the full article and related Commentary.
Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2
*Click on the links to the left for PDFs of the full article and related Commentary.
Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2
*Click on the links to the left for PDFs of the full article and related Commentary.